================================================================================



                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): September 4, 2007

                              ONCOLOGIX TECH, INC.
            ---------------------------------------------------------
           (Name of Small Business Issuer as Specified in Its Charter)

                                     0-15482
                             ----------------------
                            (Commission File Number)

            Nevada                                                86-1006416
 ------------------------------                               -----------------
(State or other jurisdiction of                              (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                    3725 Lawrenceville-Suwanee Rd., Suite B-4
                                Suwanee, GA 30024
                     --------------------------------------
                    (Address of principal executive offices)

                                 (770) 831-8818
                             ------------------------
                           (Issuer's telephone number)

Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



================================================================================




Item 8.01     Other Events.

         Mr. Stanley L. Schloz, a director and our Chairman, agreed to advance
$150,000 to the Company pursuant to a convertible promissory note, to be dated
September 4, 2007, in that principal amount, to accrue interest at the rate of
1% per month, to be paid monthly. The principal and accrued interest under the
promissory note is convertible into our common stock at the rate of $0.20 per
share. In addition, Mr. Anthony Silverman, another of our directors, agreed to
extend payment on aggregate principal indebtedness of approximately $880,450 to
December 15, 2007. The $880,450 in aggregate principal consists of a $200,000
promissory note, a $400,000 promissory note, an $80,450 convertible promissory
note and a $200,000 convertible promissory note.

         Mountainview Opportunistic Growth Fund, L.P., an Ontario limited
partnership, agreed to extend repayment under our $350,000 promissory note until
January 15, 2008, and in consideration of that extension, we have decreased the
per share stock conversion price under that promissory note from $1.00 to $0.20.




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.


Dated: September 7, 2007                  ONCOLOGIX TECH INC.


                                          By:  /s/  Andrew M. Green
                                             ----------------------------------
                                                    Andrew M. Green,
                                                    Chief Executive Officer and
                                                    President

                                          By:  /s/  Michael A. Kramarz
                                             ----------------------------------
                                                    Michael A. Kramarz,
                                                    Chief Financial Officer